Evolutionary biology in particular is not new to political controversies. Over the past century, it has been at the center of several high-profile legal battles. Most famous are the debates about the ...

The perceived failure of current drug discovery has generated widespread concern, and several divergent opinions about the problem and its potential solutions. Horrobin 1 has gone so far as to liken ...

In the past three decades, target-based drug discovery (TDD) — in which the starting point is a defined molecular target that is hypothesized to have an important role in disease — has been the ...

SOMERVILLE, Mass.--(BUSINESS WIRE)-- Generate:Biomedicines (“Generate”) today announced a multi-target collaboration with Novartis (NYSE: NVS) to discover and develop protein therapeutics across ...

— Companies will co-develop inhibitors of a dark kinase target (NEK1) identified for cancer dependency by Turbine’s Simulated Cell™ platform — LONDON & BUDAPEST, Hungary & NEW YORK--(BUSINESS ...

Generate:Biomedicines and Novartis have entered into a multi-target partnership, focusing on the discovery and development of protein therapeutics in multiple disease areas. Their collaboration will ...

During the last few decades, the strategy used to discover molecular predictors was based on retrospective biomarker analyses of phase II/III trials performed in all comers. This approach was ...

TORONTO, July 24, 2023 /PRNewswire/ - ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological ...

Novartis will apply Generate:Biomedicines’ generative artificial intelligence (AI) platform to discover and develop protein therapeutics for multiple unspecified disease areas, through a collaboration ...

Our centre’s focus is to build robust target validation data packages against potential cancer targets identified by the ICR's researchers across Divisions. This is to increase confidence in the ...

Explore the role of patient-derived biology in enhancing antibody-drug conjugates for more effective cancer treatment.

NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced the initiation of its first target validation efforts through the Targets to ...